How do we use the National Healthcare Safety Network for Hemovigilance in Massachusetts?

Autor: Iannone A; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Cumming M; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Osinski A; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Brandeburg C; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Schultz J; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Slider A; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Rodrigue B; Division of Laboratory and Transfusion Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., O'Hearn L; Transfusion Medicine Service, Baystate Health, Springfield, Massachusetts, USA., Herman M; Division of Laboratory and Transfusion Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., McHale E; Bureau of Health Care Safety and Quality, Massachusetts Department of Public Health, Boston, Massachusetts, USA., Rios J; American Red Cross Blood Services, Dedham, Massachusetts, USA., Uhl L; Division of Laboratory and Transfusion Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Andrzejewski C Jr; System Blood Banking and Transfusion/Apheresis Medicine Services, Department of Pathology, Baystate Medical Center, Springfield, Massachusetts, USA., DeMaria A Jr; Division of Epidemiology, Bureau of Infectious Disease and Laboratory Sciences, Massachusetts Department of Public Health, Boston, Massachusetts, USA.
Jazyk: angličtina
Zdroj: Transfusion [Transfusion] 2024 Feb; Vol. 64 (2), pp. 200-209. Date of Electronic Publication: 2023 Dec 30.
DOI: 10.1111/trf.17689
Abstrakt: Background: Use of the National Healthcare Safety Network (NHSN) has been essential to the success of the Massachusetts Hemovigilance Program and has allowed for the timely identification of signals and trends over a defined population that correlate with national and international hemovigilance (HV) data. Here, we outline how the NHSN system is used for monitoring HV data in Massachusetts and encourage adoption of NHSN for nationwide HV surveillance.
Study Design and Methods: A collaboration that grew over time between local HV stakeholders and the Massachusetts Department of Public Health (MDPH) resulted in the change from a paper-based method of reporting adverse reactions and monthly transfusion activity for compliance with state requirements to replacement with statewide adoption of reporting via NHSN.
Results: Over 1.5 million blood products were transfused in Massachusetts between 2017 and 2021, with 3000 adverse reactions among 10 defined types reported. Using NHSN, MDPH has been able to produce numerous reports, publications, and presentations that have made previously non-obtainable HV and blood utilization data available.
Discussion: Although limitations to these self-reported data exist, such as lack of external validation, successful statewide implementation of NHSN for hospital blood bank reporting is possible and has benefits beyond those for regulatory oversight. It results in standardized, actionable data at both the hospital and state level, enabling inter-facility comparisons, benchmarking, and opportunities for practice improvement.
(© 2023 AABB.)
Databáze: MEDLINE
Externí odkaz: